Condition

Hepatic Impairment clinical trials and research

• 14Clinical trials
• 3Countries

Newest Hepatic Impairment clinical trials

All recruiting trials (14)

• Casdatifan pharmacokinetics in moderate hepatic impairment vs normal liver function

  This study tests how a single dose of casdatifan behaves in people with moderate liver impairment compared to healthy individuals with normal liver function.

  Recruiting Phase 1 Arcus Biosciences, Inc. · San Antonio, Texas · NCT07751250

• How the medicine Atirmociclib behaves in people with healthy liver or with liver disease

  This study tests how atirmociclib is processed in the body and how safe it is for adults with normal liver function or with stable mild to severe liver disease.

  Recruiting at 3 sites Phase 1 Pfizer · Miami Lakes, Florida and 2 other locations · NCT07677358

• Treprostinil Palmitil Inhalation Powder: how liver function affects drug in a single-dose test

  This study tests how mild to severe liver impairment changes the amount of treprostinil palmitil and treprostinil in the body after one 80 mcg dose of TPIP in people with and without liver problems.

  Recruiting at 4 sites Phase 1 Insmed Incorporated · Lake Forest, California and 3 other locations · NCT07643155

• How liver impairment affects AZD9550 and AZD6234

  This trial will test how single subcutaneous doses of two investigational drugs, AZD9550 and AZD6234, are processed and tolerated in adults with moderate or severe liver impairment compared with matched healthy volunteers.

  Recruiting at 3 sites Phase 1 AstraZeneca · Chandler, Arizona and 3 other locations · NCT07546760

• How BI 3000202 behaves in the blood in people with and without liver problems

  This study tests how BI 3000202 moves through the body in healthy adults and adults with liver impairment.

  Recruiting Phase 1 Boehringer Ingelheim · San Antonio, Texas · NCT07486102

• Radiprodil for adults with liver impairment

  It will test whether a single 15 mg oral dose of radiprodil is processed differently and tolerated safely in adults with mild, moderate, or severe liver impairment compared with healthy adults.

  Recruiting at 2 sites Phase 1 GRIN Therapeutics, Inc. · DeSoto, Texas and 1 other locations · NCT07457229

• How PF-07328948 is processed in people with and without reduced liver function

  Adults with and without reduced liver function will take a single dose of PF-07328948 to see how their bodies process the medicine.

  Recruiting at 3 sites Phase 1 Pfizer · Lake Forest, California and 2 other locations · NCT07269301

• How the medicine BI 1291583 gets into the blood of people with and without liver problems.

  This will test how a single oral dose of BI 1291583 enters the bloodstream in adults with and without liver impairment.

  Recruiting Phase 1 Boehringer Ingelheim · Rialto, California and 3 other locations · NCT07023354

• Impact of liver function on how the body processes Mirdametinib

  This study is testing how well the body processes a drug called Mirdametinib in people with liver problems compared to healthy volunteers to see if there are any differences in how the drug works.

  Recruiting at 3 sites Phase 1 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Miami, Florida and 2 other locations · NCT06997276

• Evaluating the effects of hepatic impairment on HDM1002

  This study tests how different levels of liver function affect the way the drug HDM1002 works in Chinese adults aged 18-70.

  Recruiting Phase 1 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Suzhou, Jiangsu · NCT06985615

• Single-dose zanzalintinib testing in people with moderate liver impairment

  This will test how one dose of zanzalintinib behaves in the blood of people with moderate liver impairment compared with healthy people.

  Recruiting at 2 sites Phase 1 Exelixis · Orlando, Florida and 1 other locations · NCT06962332

• Evaluating quizartinib in patients with severe liver impairment

  This study is testing how a single dose of quizartinib affects people with severe liver problems compared to healthy individuals to see if it's safe and how the body processes the medication.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Miami, Florida and 2 other locations · NCT06740799

• Treatment for liver impairment in patients with cirrhosis from cholestatic liver disease

  This study is testing a new medication called Saroglitazar Magnesium to see if it can improve liver function and health in people with cirrhosis from cholestatic liver disease.

  Recruiting Phase 1 Zydus Therapeutics Inc. · Indianapolis, Indiana · NCT05045482

• Evaluating the effects of tasurgratinib in patients with mild to moderate liver impairment

  This study tests how well the drug tasurgratinib works in people with mild to moderate liver problems compared to healthy individuals.

  Recruiting at 7 sites Phase 1 Eisai Inc. · Hakata, Fukuoka and 7 other locations · NCT04271488

Related topics

Quick answers

How many Hepatic Impairment clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in United States (12 trials), Japan (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 14. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →